AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.



Biotechnology

AC Immune

Andrea Pfeifer

Christopher R.

Madiha Derouazi

Nuno Mendonça

Bojana Portmann

Julien Rongère

Alexandre Caratsch

Marie Kosco-Vilbois

Piergiorgio Donati

Christopher Roberts

Jean-Fabien Monin

Howard Donovan

The leadership team at AC Immune has experience in a variety of fields, including immunology, anatomy, and biology. They have worked at companies such as NovImmune, Serono SA, and Glaxo Wellcome Research Institute. They have also studied at a variety of schools, including Virginia Commonwealth University School of Medicine and Douglass College at Rutgers University.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at AC Immune

Board of Directors

CEO and Executive Team